Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03898297 · ClinicalTrials.gov registry record
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
A clinical trial of Healthy and Major Depressive Disorder, sponsored by Yale University.
- Active
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT03898297: Active study of Healthy and Major Depressive Disorder, sponsored by Yale University.
NCT03898297 is a study of Healthy and Major Depressive Disorder that is active but no longer recruiting, run by Yale University. The registered enrollment target is 120 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03898297, a study of Healthy and Major Depressive Disorder, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is designed to look at the involvement of the glutamate system and synaptic density in depression and bipolar disorder. Each participant will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of a combination of one magnetic resonance imaging (MRI) or functional magnetic resonance imaging (fMRI) scan, one proton magnetic resonance spectroscopy (MRS) and/or one C13 MRS scans, and up to two positron emission tomography (PET) scans. Participants will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.
Primary Outcome
Glutamate (major excitatory neurotransmitter)is widespread throughout the brain \& likely modulates some symptoms present in individuals w/mood disorders. Glutamate neurotransmission is regulated by ionotropic \& the G-protein coupled metabotropic glutamate receptors (mGluR) which are divided into 3 groups: group I (mGluR1 and 5), group II (mGluR2 and 3) \& group III (mGluR4, 6, 8). The group I mGluRs couple to phospholipase C, \& stimulate cyclic AMP formation \& arachidonic acid release \& thu
Conditions Studied
Interventions
- RADIATION [18F]FPEB
- RADIATION [11C]APP311
Study Locations (1)
Connecticut
- Yale University PET Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2026-04 |
What the registry record for NCT03898297 still lists
NCT03898297 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which [18F]FPEB is the first listed.
NCT03898297 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03898297 about?
NCT03898297 is a clinical study titled "Imaging mGluR5 and Synaptic Density in Psychiatric Disorders". This research study is designed to look at the involvement of the glutamate system and synaptic density in depression and bipolar disorder. Each participant will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availa...
What is the current status of trial NCT03898297?
This trial is currently active not recruiting. The enrollment target is 120 participants. The study started on 2017-01-11. Estimated completion is 2026-04.
What conditions does trial NCT03898297 study?
This clinical trial studies the following conditions: Healthy, Major Depressive Disorder, Bipolar Disorder.
What interventions are being tested in trial NCT03898297?
The interventions under investigation include: [18F]FPEB (RADIATION), [11C]APP311 (RADIATION).
Who is sponsoring clinical trial NCT03898297?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03898297 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03898297's enrollment target sits among peer trials
120 182nd of 1090 higher than 896 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI